Ferroptosis: The Iron-Linked Heart Failure Nexus and Its Druggable Pathways
A comprehensive review in Cardiovascular Research synthesizes evidence on ferroptosis, a form of regulated cell death driven by iron-dependent lipid peroxidation, as a key contributor to heart failure progression. The analysis details how disordered iron handling, antioxidant failure, and mitochondrial stress converge in various cardiomyopathy models, leading to contractile dysfunction. Crucially, the review highlights that established cardiometabolic drugs with proven clinical efficacy—including Sodium–Glucose Cotransporter 2 (SGLT2) inhibitors, sacubitril/valsartan, and the non-steroidal mineralocorticoid receptor antagonist finerenone—demonstrate multi-layer rescue effects, restoring cardiac function and reversing adverse remodelling in preclinical studies. Early human evidence aligns, showing that patients on SGLT2 inhibitors exhibit reduced ferroptosis activity in circulating biomarkers and tissue profiles.
Why it might matter to you:
This mechanistic framework directly connects the therapeutic benefits of several major drug classes to a specific, modifiable cell death pathway, offering a new lens for understanding their pharmacodynamics. For pharmacology professionals, it underscores the importance of drug metabolism and excretion pathways related to iron homeostasis and oxidative stress in therapeutic drug monitoring and the development of novel targeted agents. The proposed “ferroptosis nexus” could inform future clinical trials and the pursuit of precision cardioprotection strategies.
Stay curious. Stay informed — with
Science Briefing.
Always double check the original article for accuracy.
